Hormonal
Dietary polyphenols prevent and manage Type 2 diabetes mellitus through insulin-dependent mechanisms (protection of pancreatic islet β-cells, reduction of apoptosis, promotion of proliferation, attenuation of oxidative stress, activation of insulin signaling, and stimulation of insulin secretion) and insulin-independent mechanisms (inhibition of glucose absorption, inhibition of digestive enzymes, regulation of intestinal microbiota, modification of inflammation response, and inhibition of advanced glycation end products formation).
Incorporate polyphenol-rich foods (like berries, tea, coffee, and wine) into your diet as part of a broader strategy for managing Type 2 Diabetes. Do not rely on isolated polyphenol supplements as a substitute for prescribed medication, as clinical evidence for their standalone therapeutic effect is currently limited.
Dietary polyphenols prevent and manage Type 2 diabetes mellitus via the insulin-dependent approaches, for instance, protection of pancreatic islet 𝛽-cell, reduction of 𝛽-cell apoptosis, promotion of 𝛽-cell proliferation, attenuation of oxidative stress, activation of insulin signaling, and stimulation of pancreas to secrete insulin, as well as the insulin-independent approaches including inhibition of glucose absorption, inhibition of digestive enzymes, regulation of intestinal microbiota, modification of inflammation response, and inhibition of the formation of advanced glycation end products.
Why this rating
The paper is a review highlighting advances; it cites numerous in vivo/in vitro studies but explicitly states clinical data is 'very limited' and 'individual flavoid... has no therapeutic effect on diabetic patients'.
Source
Dietary polyphenols as antidiabetic agents: Advances and opportunities
Chongde Sun et al. · Food Frontiers · 2020
DOI 10.1002/fft2.15
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →